Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab in Coronary Artery Disease
NCT06572267Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of meplazumab in coronary artery disease (CAD) (4 arms), sponsored by Xijing Hospital. Primary endpoint: Proportion of high PVAT attenuation coefficient among non-target lesion(s) at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
meplazumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06572267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572267.